Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 10/20 | 0.39 |
| ▸ | JAK1 | P23458 | 10/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784022 | 0.91 | TLR9 (0.42) | TLR9TLR8TLR7F10JAK2 | |
| SCHEMBL785264 | 0.89 | TLR9 (0.41) | TLR9TLR8TLR7F10POLB | |
| SCHEMBL784016 | 0.87 | F10 (0.43) | TLR9TLR8TLR7F10JAK2 | |
| SCHEMBL785091 | 0.87 | ACHE (0.43) | ACHEF10JAK2JAK1POLB | |
| SCHEMBL785459 | 0.87 | TSHR (0.41) | TLR9TLR8TLR7ACHEF10 | |
| SCHEMBL784886 | 0.87 | F10 (0.41) | TLR9TLR8TLR7ACHEF10 | |
| SCHEMBL803662 | 0.87 | TLR9 (0.39) | TLR9TLR8TLR7F10JAK2 | |
| SCHEMBL784473 | 0.87 | DRD2 (0.42) | TLR9TLR8TLR7F10JAK2 | |
| SCHEMBL785591 | 0.86 | F10 (0.44) | TLR9TLR8TLR7ACHEF10 | |
| SCHEMBL785386 | 0.86 | KCNQ2 (0.39) | TLR9TLR8TLR7F10JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| CN-103097354-A | Substituted benzamide compounds | GRUENENTHAL CHEMIE | 2013-05-08 | — | — | CN | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TLR9 1200/4885TLR8 1055/4885TLR7 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.